Tamsulosin controlled-release - GL PharmTech

Drug Profile

Tamsulosin controlled-release - GL PharmTech

Alternative Names: GL2702; GL2702 GLARS-NF1; GLC2TA; Incrementally modified tamsulosin; Tamsulosin GLARS; Tamsulosin new QD; Tamsulosin OD

Latest Information Update: 07 Mar 2016

Price : $50

At a glance

  • Originator GL PharmTech
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia

Most Recent Events

  • 01 Oct 2015 GL PharmTech completes a phase III trial in Benign prostatic hyperplasia in South Korea (NCT02303769) (PO, 0.4mg)
  • 06 May 2015 Discontinued for Benign prostatic hyperplasia in South Korea (PO, 0.2mg)
  • 06 May 2015 Controlled-release tamsulosin is still in phase III trials for Benign prostatic hyperplasia in South Korea (PO, 0.4mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top